Bruno Gagnon1, Graeme Low, Gil Schreier. 1. Division of Palliative Care, Department of Oncology, McGill University Health Centre, Montréal, Que. bruno.gagnon@clinepi.mcgill.ca
Abstract
OBJECTIVE: To investigate the clinical improvement observed in patients with advanced cancer and hypoactive delirium after the administration of methylphenidate hydrochloride. METHODS: Fourteen patients with advanced cancer and hypoactive delirium were seen between March 1999 and August 2000 at the Palliative Care Day Hospital and the inpatient Tertiary Palliative Care Unit of Montreal General Hospital, Montreal. They were chosen for inclusion in a prospective clinical study on the basis of (1) cognitive failure documented by the Mini-Mental State Examination (MMSE), (2) sleep-wake pattern disturbances, (3) psychomotor retardation, (4) absence of delusions or hallucinations, and (5) absence of an underlying cause to explain the delirium. All patients were treated with methylphenidate, and changes in their cognitive function were measured using the MMSE. RESULTS: All 14 patients showed improvement in their cognitive function as documented by the MMSE. The median pretreatment MMSE score (maximum score 30) was 21 (mean 20.9, standard deviation [SD] 4.9), which improved to a median of 27 (mean 24.9, SD 4.7) after the first dose of methylphenidate (p < 0.001, matched, paired Wilcoxon signed rank test). One patient died before reaching a stable dose of methylphenidate. In the other 13 patients, the median MMSE score further improved to 28 (mean 27.8, SD 2.4) (p = 0.02 compared with the median MMSE score documented 1 hour after the first dose of methylphenidate). All patients showed an improvement in psychomotor activities. CONCLUSIONS: Hypoactive delirium that cannot be explained by an underlying cause (metabolic or drug-induced) in patients with advanced cancer appears to be a specific syndrome that could be improved by the administration of methylphenidate.
OBJECTIVE: To investigate the clinical improvement observed in patients with advanced cancer and hypoactive delirium after the administration of methylphenidate hydrochloride. METHODS: Fourteen patients with advanced cancer and hypoactive delirium were seen between March 1999 and August 2000 at the Palliative Care Day Hospital and the inpatient Tertiary Palliative Care Unit of Montreal General Hospital, Montreal. They were chosen for inclusion in a prospective clinical study on the basis of (1) cognitive failure documented by the Mini-Mental State Examination (MMSE), (2) sleep-wake pattern disturbances, (3) psychomotor retardation, (4) absence of delusions or hallucinations, and (5) absence of an underlying cause to explain the delirium. All patients were treated with methylphenidate, and changes in their cognitive function were measured using the MMSE. RESULTS: All 14 patients showed improvement in their cognitive function as documented by the MMSE. The median pretreatment MMSE score (maximum score 30) was 21 (mean 20.9, standard deviation [SD] 4.9), which improved to a median of 27 (mean 24.9, SD 4.7) after the first dose of methylphenidate (p < 0.001, matched, paired Wilcoxon signed rank test). One patient died before reaching a stable dose of methylphenidate. In the other 13 patients, the median MMSE score further improved to 28 (mean 27.8, SD 2.4) (p = 0.02 compared with the median MMSE score documented 1 hour after the first dose of methylphenidate). All patients showed an improvement in psychomotor activities. CONCLUSIONS:Hypoactive delirium that cannot be explained by an underlying cause (metabolic or drug-induced) in patients with advanced cancer appears to be a specific syndrome that could be improved by the administration of methylphenidate.
Authors: J Homsi; K A Nelson; N Sarhill; L Rybicki; S B LeGrand; M P Davis; D Walsh Journal: Am J Hosp Palliat Care Date: 2001 Nov-Dec Impact factor: 2.500
Authors: Carmen P Escalante; Christina Meyers; James M Reuben; Xuemei Wang; Wei Qiao; Ellen Manzullo; Ricardo H Alvarez; Phuong Khanh Morrow; Ana M Gonzalez-Angulo; Xin Shelley Wang; Tito Mendoza; Wenli Liu; Holly Holmes; Jessica Hwang; Katherine Pisters; Michael Overman; Charles Cleeland Journal: Cancer J Date: 2014 Jan-Feb Impact factor: 3.360
Authors: K Gehring; S Y Patwardhan; R Collins; M D Groves; C J Etzel; C A Meyers; J S Wefel Journal: J Neurooncol Date: 2011-10-02 Impact factor: 4.130
Authors: Shirley H Bush; Salmaan Kanji; José L Pereira; Daniel H J Davis; David C Currow; David Meagher; Kiran Rabheru; David Wright; Eduardo Bruera; Michael Hartwick; Pierre R Gagnon; Bruno Gagnon; William Breitbart; Laura Regnier; Peter G Lawlor Journal: J Pain Symptom Manage Date: 2014-01-28 Impact factor: 3.612
Authors: Gisele Pereira Dias; Ronan Hollywood; Mário Cesar do Nascimento Bevilaqua; Anna Claudia Domingos da Silveira da Luz; Robert Hindges; Antonio Egidio Nardi; Sandrine Thuret Journal: Neuro Oncol Date: 2014-01-26 Impact factor: 12.300